Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F23%3A10472797" target="_blank" >RIV/00064165:_____/23:10472797 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10472797
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=GzdP_WPSev" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=GzdP_WPSev</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clml.2023.08.018" target="_blank" >10.1016/j.clml.2023.08.018</a>
Alternative languages
Result language
angličtina
Original language name
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
Original language description
Efficacy and tolerability data of 195 patients with relapsed/refractory multiple myeloma who were randomized to once-weekly selinexor (100 mg), once-weekly subcutaneous bortezomib, and twice-weekly dexamethasone in the BOSTON study were compared between patients who had selinexor dose reductions (n = 126) and those who did not (n = 69). Selinexor dose reduction was associated with longer progression-free survival, better overall response, lower duration-adjusted adverse event rates and improved quality of life. Background: Dose modifications in response to adverse events (AEs) can maintain tumor response and improve therapy tolerability. We conducted a post-hoc analysis of the efficacy and safety of reduced selinexor doses in the BOSTON trial (NCT03110562). Patients and Methods: Efficacy, safety, and quality of life (QoL) in 195 patients with relapsed/refractory multiple myeloma randomized to once-weekly (QW) selinexor (100 mg), QW subcutaneous bortezomib (1.3 mg/m2), and twice-weekly dexamethasone (20 mg) were compared between patients with dose reductions and those without. Results: In total, 126 patients (65%) had selinexor dose reductions (median dose 71.4 mg/wk). In patients with dose reductions versus those without median progression-free survival was 16.6 months (95% CI 12.9-not evaluable [NE]) versus 9.2 months [95% CI 6.8-15.5]), overall response rate was 81.7% (95% CI 73.9-88.1%) versus 66.7% (95% CI 54.3-77.6%), >= very good partial response was (51.6% [95% CI 42.5-60.6%] vs. 31.9% [95% CI 21.244.2]), median duration of response was not reached (95% CI 13.8-NE) versus 12.0 months (95% CI 8.3-NE), and time to next treatment was 22.6 months (95% CI 14.6-NE) versus 10.5 months (95% CI 6.3-18.2). Mean best change from baseline on the EORTC QLQ-C30 Global Health Status/QoL scale was 10.0 +/- 20.5 versus 4.0 +/- 20.9. Duration adjusted AE rates that were lower after selinexor dose reduction included thrombocytopenia (62.5% before vs. 47.6% after), nausea (31.6% vs. 7.3%), fatigue (28.1% vs. 9.9%), decreased appetite (21.5% vs. 6.4%), anemia (17.9% vs. 10.3%), and diarrhea (12.9% vs. 5.2%). Conclusion: Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Lymphoma, Myeloma & Leukemia
ISSN
2152-2650
e-ISSN
2152-2669
Volume of the periodical
23
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
917-"923.e3"
UT code for WoS article
001125357500001
EID of the result in the Scopus database
2-s2.0-85171974140